MedPath

Bimagrumab

Generic Name
Bimagrumab
Drug Type
Biotech
CAS Number
1356922-05-8
Unique Ingredient Identifier
N15SW1DIV8
Background

Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.

Clinical Trials
Related News

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Phase 2
Not yet recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Bimagrumab Placebo
First Posted Date
2025-03-28
Last Posted Date
2025-04-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
180
Registration Number
NCT06901349
Locations
🇺🇸

Yuma Clinical Trials, Yuma, Arizona, United States

🇺🇸

Orange County Research Center, Lake Forest, California, United States

🇺🇸

Healthy Brain Clinic, Long Beach, California, United States

and more 45 locations

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: Bimagrumab + Tirzepatide Coformulation
First Posted Date
2025-03-24
Last Posted Date
2025-04-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
100
Registration Number
NCT06890611
Locations
🇺🇸

Fortrea Clinical Research Unit, Dallas, Texas, United States

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Phase 2
Recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Bimagrumab Placebo
First Posted Date
2024-10-16
Last Posted Date
2025-05-13
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
240
Registration Number
NCT06643728
Locations
🇺🇸

Pinnacle Research Group, LLC, Anniston, Alabama, United States

🇺🇸

Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States

🇺🇸

SKY Integrative Medical Center/SKYCRNG, Ridgeland, Mississippi, United States

and more 9 locations

Effect of Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults with Obesity

Phase 2
Not yet recruiting
Conditions
Obesity
Interventions
Drug: IV placebo
Dietary Supplement: Calcium/Vitamin D
Behavioral: Lifestyle and nutrition counseling
First Posted Date
2023-07-06
Last Posted Date
2025-03-11
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
65
Registration Number
NCT05933499

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Phase 2
Active, not recruiting
Conditions
Obesity
Overweight or Obesity
Obese
Interventions
Other: Bimagrumab Placebo
First Posted Date
2022-11-14
Last Posted Date
2025-02-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
507
Registration Number
NCT05616013
Locations
🇳🇿

Middlemore Hospital, Auckland, New Zealand

🇦🇺

Emeritus Research, Camberwell, Australia

🇳🇿

Lakeland Clinical Trials Waikato, Hamilton, New Zealand

and more 23 locations

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Phase 3
Completed
Conditions
Sporadic Inclusion Body Myositis
Interventions
Drug: Placebo
First Posted Date
2015-10-09
Last Posted Date
2018-03-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
211
Registration Number
NCT02573467
Locations
🇬🇧

Novartis Investigative Site, Newcastle upon Tyne, United Kingdom

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

Phase 2
Completed
Conditions
Sarcopenia
Interventions
Drug: Placebo
First Posted Date
2015-06-11
Last Posted Date
2020-06-16
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
160
Registration Number
NCT02468674
Locations
🇨🇳

Novartis Investigative Site, Taipei, Taiwan

Dose Range Finding Study of Bimagrumab in Sarcopenia

Phase 2
Completed
Conditions
Sarcopenia
Interventions
Other: placebo
First Posted Date
2015-01-07
Last Posted Date
2021-01-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
217
Registration Number
NCT02333331
Locations
🇨🇳

Novartis Investigative Site, Taipei, Taiwan

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Phase 2
Completed
Conditions
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Interventions
Other: placebo
First Posted Date
2014-06-02
Last Posted Date
2020-08-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
251
Registration Number
NCT02152761
Locations
🇬🇧

Novartis Investigative Site, Bath, United Kingdom

Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients

Phase 2
Withdrawn
Conditions
Mechanical Ventilation
Interventions
Drug: Placebo
First Posted Date
2013-06-04
Last Posted Date
2015-01-07
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT01868685
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy